GH Research (GHRS)
(Real Time Quote from BATS)
$11.35 USD
+0.05 (0.44%)
Updated Jul 10, 2024 03:25 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
GH Research PLC [GHRS]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Lykos Lessons: Functional Unblinding, Treatment Durability, Role of Psychotherapy, Safety, and a Proposed REMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
1Q24 Results; Progressing Toward Key Data Readouts in 2H24 and 1Q25; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs Psychiatry Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
4Q23 Results; Psychedelic GH001 on Track For Phase 2 Data in TRD in 2H24, and in PPD in 3Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Lead Short-Acting Psychedelic GH001 Progressing in Multiple Phase 2 Trials With Near-Term Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for GHRS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
GH001 Phase 2b Data on Track For 2H24; Meeting With FDA on Bridging Study Hold in 1Q24; Moderating PT to $40; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
GH001 Phase 2b Top-line Data on Track For 2H24; Phase 1 Trial to Evaluate Novel Aerosol Device Delayed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
2Q23 Results; Short-Acting Psychedelic GH001 Progressing in Several Depression Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Takeaways From Recent Conferences: Nearing a Psychedelic Breakout With Plethora of Catalysts; LP352 to Shine in Epilepsy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
GH001 Advancing in Multiple Phase 2 Depression Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
4Q22 Results; GH001 Advances to Phase 2b in TRD; Bipolar Depression and PPD Programs Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Bullish Start to the Year for Psychedelic Drug Development Companies Ahead of a Plethora of Potential Positive Events
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
3Q22 Results; Short-Acting Psychedelic GH001 Progressing in Depression; Multiple Program Updates Expected in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
JAMA Publication Further Supports Psychedelic Approach to Treat Alcoholism, a Potential $20B-Plus Global Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Leader in Emerging $400B Mental Healthcare Market Nearing Phase 2b Development of Lead Depression Drug; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: GH Research PLC
Industry: Medical - Biomedical and Genetics
Change Your Mind: Outlining Mental Healthcare Treatments of the Future With $400B Annual Revenue Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P